Ramos, Christian, Efreen Montaño, Alfonso Reyes-López, Fabiola Lemus, Maria Pacheco, Gabriela Hernandez, and Arely Lemus. “Economic Evaluation of Lenalidomide (Revlimid®) for the Treatment of Mielodysplastic Syndrome With 5q Deletion at low/Intermediate-1 Risk: Evaluación Económica De Lenalidomida (Revlimid®) Para El Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q De Riesgo Bajo/Intermedio-1”. Global and Regional Health Technology Assessment 4, no. 1 (November 11, 2019): 133–140. Accessed November 21, 2024. https://journals.aboutscience.eu/index.php/grhta/article/view/387.